World Health Organization approves China’s Sinovac Covid-19 vaccine for emergency use


This decision will allow CoronaVac to be used in WHO’s vaccine-sharing program, kovaxwho wants to provide same global reach for vaccination.

WHO Director-General Tedros Adhanom Ghebreyesus said in a news briefing on Tuesday that the coronavirus “Found to be safe, effective and quality-assured after two doses of the inactivated vaccine.”

WHO’s Strategic Advisory Group of Experts on Immunization (SAGE) recommends the vaccine for people over the age of 18. Two doses should last between two and four weeks.

Unlike some other vaccines, CoronaVac does not need to be stored at extremely cold temperatures.

“CoronaVac’s easy storage requirements make it very suitable for low-resource settings,” Tedros said. “Now it’s important to get these life-saving devices to the people who need them quickly.”

efficacy studies have shown The WHO said in a statement, CoronaVac prevented symptomatic disease in more than half of those vaccinated and 100% of those with severe COVID-19 and hospitalizations.

It is the eighth vaccine to receive emergency use list from WHO including Pfizer/BioNtech, AstraZeneca, Moderna, Jenson (Johnson & Johnson) and Serum Institute of India.

the world needs more food

here is urgent For Kovid-19 vaccines in places where the coronavirus is increasing and what has been done in those countries unable to buy sufficient dosage.
It is hoped that the Sinovac approval will boost the supply of COVAX, the global vaccine-sharing program. The program has recently faced a serious Shortage of supply from India, which halted exports of the AstraZeneca vaccine amid its COVID-19 crisis. Western countries have also been criticized for their stockpile of vaccines.
The world's largest vaccine maker company is stalled on exports.  This is the most vulnerable problem for the planet
COVAX should have already delivered 170 million total doses, accordingly According to a recent report by the United Nations Children’s Fund (UNICEF). Instead, as of May 17, it had delivered 71 million shots in 125 countries and territories.

“The world is in dire need of multiple COVID-19 vaccines to address the massive access disparity around the world,” Mariangela Simo, WHO’s assistant-director-general for access to health products, said in a statement.

“We urge manufacturers to participate in the COVAX facility, share their knowledge and data, and contribute to bringing the epidemic under control.”

China supplies vaccines

Both Sinovac and Sinoform shots are inactivated vaccines, which are lower in efficacy than the mRNA vaccines produced by Pfizer-BioNtech and Moderna.

Unlike their Western counterparts, the two Chinese companies have not released complete data on their final phase clinical trials conducted around the world, which has been criticized by scientists and health experts.

As China awaits WHO approval for its vaccines, one country is sending back its vaccines

According to Sinopharm and Sinovac, their vaccines received varying efficacy results in trials conducted in different countries, but they all exceeded the WHO’s 50% efficacy limit for emergency use approval.

Sinovac has already provided shots to dozens of countries and territories, including mainland China, the Philippines, Indonesia, Turkey, Chile, Mexico and Brazil. the company said It has supplied over 600 million doses of its vaccine domestically and internationally, with over 430 million doses administered.

On Tuesday, China said it had produced the first batch of its SinoPharm vaccines to be distributed to COVAX, according to state media Xinhua. China’s global vaccine sharing plan plans to deliver 10 million doses.

CNN’s James Griffiths contributed reporting.


Source link